Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
Removal of bone marrow and evaluation of its histologic picture.

Clusters of Pneumocystis carinii pneumonia: analysis of person-to-person transmission by genotyping. (1/1889)

Genotyping at the internal transcribed spacer (ITS) regions of the nuclear rRNA operon was performed on isolates of P. carinii sp. f. hominis from three clusters of P. carinii pneumonia among eight patients with haematological malignancies and six with HIV infection. Nine different ITS sequence types of P. carinii sp. f. hominis were identified in the samples from the patients with haematological malignancies, suggesting that this cluster of cases of P. carinii pneumonia was unlikely to have resulted from nosocomial transmission. A common ITS sequence type was observed in two of the patients with haematological malignancies who shared a hospital room, and also in two of the patients with HIV infection who had prolonged close contact on the ward. In contrast, different ITS sequence types were detected in samples from an HIV-infected homosexual couple who shared the same household. These data suggest that person-to-person transmission of P. carinii sp. f. hominis may occur from infected to susceptible immunosuppressed patients with close contact within hospital environments. However direct transmission between patients did not account for the majority of cases within the clusters, suggesting that person-to-person transmission of P. carinii sp. f. hominis infection may be a relatively infrequent event and does not constitute the major route of transmission in man.  (+info)

TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. (2/1889)

The TEL/PDGFbetaR fusion protein is expressed as the consequence of a recurring t(5;12) translocation associated with chronic myelomonocytic leukemia (CMML). Unlike other activated protein tyrosine kinases associated with hematopoietic malignancies, TEL/PDGFbetaR is invariably associated with a myeloid leukemia phenotype in humans. To test the transforming properties of TEL/PDGFbetaR in vivo, and to analyze the basis for myeloid lineage specificity in humans, we constructed transgenic mice with TEL/PDGFbetaR expression driven by a lymphoid-specific immunoglobulin enhancer-promoter cassette. These mice developed lymphoblastic lymphomas of both T and B lineage, demonstrating that TEL/PDGFbetaR is a transforming protein in vivo, and that the transforming ability of this fusion is not inherently restricted to the myeloid lineage. Treatment of TEL/PDGFbetaR transgenic animals with a protein tyrosine kinase inhibitor with in vitro activity against PDGFbetaR (CGP57148) resulted in suppression of disease and a prolongation of survival. A therapeutic benefit was apparent both in animals treated before the development of overt clonal disease and in animals transplanted with clonal tumor cells. These results suggest that small-molecule tyrosine kinase inhibitors may be effective treatment for activated tyrosine kinase-mediated malignancies both early in the course of disease and after the development of additional transforming mutations.  (+info)

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. (3/1889)

We analysed 57 patients with non-myeloid malignancies who received a non-purged autologous PBSCT. All had similar mobilisation and conditioning regimens. A high prior chemotherapy score and the number of chemotherapy lines used (P = 0.015 and P = 0.01, respectively) were adverse predictors of CD34 cell yields. Lower CD34 values (P = 0.002) were seen in patients treated with potent stem cell toxins (BCNU, melphalan, CCNU and mustine), designated toxicity factor 4 agents (TF4). All patients infused with grafts containing CD34 cell doses between 1.0 and 2.0 x 10(6)/kg (range 1.25-1.90) engrafted by day 51. The only variable associated with slow platelet recovery was exposure to TF4 (P = 0.007). The majority of patients with CD34 >1.0 x 10(6)/kg achieved rapid and sustained engraftment and the only predictive factor of delayed recovery is prior exposure to stem cell toxins. Potential PBSCT candidates should if possible avoid first line and salvage chemotherapy containing TF4 drugs. We therefore advocate a minimum CD34 threshold of >1.0 x 10(6)/kg in patients without extensive prior chemoradiotherapy, and > or = 2.0 x 10(6)/kg in all other patients.  (+info)

Central venous catheter exchange by guidewire for treatment of catheter-related bacteraemia in patients undergoing BMT or intensive chemotherapy. (4/1889)

Current guidelines for the treatment of catheter-related bacteraemia (CRB) advise against central venous catheter (CVC) exchange because of the potential risk of prolonging infection. However, there are no consistent data proving this recommendation. We evaluated prospectively the usefulness of CVC exchange by guidewire for the treatment of CRB in patients undergoing BMT or intensive chemotherapy. CVC exchange was considered when fever and positive blood cultures persisted after 2 days of adequate antimicrobial therapy and no potential source of bacteraemia other than CVC could be identified. The guidewire exchange was preceded and followed by a slow infusion of adequate antimicrobial therapy. Bacteraemia was confirmed as catheter-related by demonstrating concordance between isolates from the tip and blood cultures by pulsed-field electrophoresis of genomic DNA. This procedure was performed in 19 episodes of bacteraemia during a 1-year period. Fourteen episodes (74%) were catheter-related and 71% of these were due to coagulase-negative staphylococci. Guidewire replacement was accomplished uneventfully 4 days after development of sepsis (range 3-6). In all cases, clinical signs of sepsis disappeared in less than 24 h after replacement. Definitive catheter withdrawal was carried out a median of 16 days (range 3-42) after guidewire exchange; in all cases, the tip culture was negative. We conclude that CVC replacement by guidewire under adequate antimicrobial therapy may be a reasonable option for the treatment of CRB when antimicrobial therapy alone has been unsuccessful.  (+info)

Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. (5/1889)

To evaluate the efficacy and safety of itraconazole oral solution for preventing fungal infections, a randomized, placebo-controlled, double-blind, multicenter trial was conducted: 405 neutropenic patients with hematologic malignancies were randomly assigned to receive either itraconazole, 2.5 mg/kg every 12 hours (201 patients), or placebo (204 patients). Proven and suspected deep fungal infection occurred in 24% of itraconazole recipients and in 33% of placebo recipients, a difference of 9 percentage points (95% confidence interval [CI], 0.6% to 22.5%; P = .035). Fungemia due to Candida species was documented in 0.5% of itraconazole recipients and in 4% of placebo recipients, a difference of 3.5 percentage points (95% CI, 0.5% to 6%; P = .01). Deaths due to candidemia occurred in none of the itraconazole recipients compared with 4 placebo recipients, a difference of 2 percentage points (95% CI, 0.05% to 4%; P = .06). Aspergillus infection was documented in four itraconazole recipients (one death) and one placebo recipient (one death). Side effects causing drug interruption occurred in 18% of itraconazole recipients and 13% of placebo recipients. Itraconazole oral solution was well-tolerated and effectively prevented proven and suspected deep fungal infection as well as systemic infection and death due to Candida species.  (+info)

Possible carcinogenic effects of X-rays in a transgenerational study with CBA mice. (6/1889)

A lifetime experiment using 4279 CBA/J mice was carried out to investigate whether the pre-conceptual exposure of sperm cells to X-ray radiation or urethane would result in an increased cancer risk in the untreated progeny, and/or increased susceptibility to cancer following exposure to a promoting agent. The study consisted of four main groups, namely a control group (saline), a urethane group (1 mg/g body wt) and two X-ray radiation groups (1 Gy, 2 Gy). At 1, 3 and 9 weeks after treatment, the males of these four parental groups were mated with untreated virgin females. The offspring of each parental group was divided into two subgroups: one received s.c. urethane (0.1 mg/g body wt once) as a promoter, the other saline, at the age of 6 weeks. All animals were evaluated for the occurrence of tumours. K-ras oncogene and p53 tumour suppressor gene mutations were investigated in frozen lung tumour samples. The female offspring of male parents exposed to X-rays 1 week before their mating showed a trend towards a higher tumour incidence of the haematopoietic system than the F1 controls. In addition, a higher percentage of bronchioloalveolar adenocarcinomas in male offspring born to irradiated paternals mated 1 week after X-ray treatment points to a plausible increased sensitivity of post-meiotic germ cell stages towards transgenerational carcinogenic effects. On the other hand, no increased tumour incidence and malignancy were observed in the offspring born to irradiated paternals mated 3 and 9 weeks after X-ray treatment. Paternal urethane treatment 1, 3 and 9 weeks prior to conception did not result in significantly altered incidence or malignancy of tumours of the lung, liver and haematopoietic tissue in the offspring. K-ras mutations increased during tumour progression from bronchioloalveolar hyperplasia to adenoma. Codon 61 K-ras mutations were more frequent in lung tumours of urethane-promoted progeny from irradiated parents than from control parents. P53 mutations were absent from these lung alterations.  (+info)

Human herpesvirus 8 in hematologic diseases. (7/1889)

Human herpesvirus type 8 (HHV-8), also known as Kaposi's sarcoma-associated herpesvirus (KSHV) is a new member of the g-herpesvirus family. It is an unusual herpesvirus in that it carries a large number of genes that encode oncoproteins or cell signaling proteins. In addition to being the causative agent of both HIV-associated and non-HIV-associated Kaposi's sarcoma this DNA tumor virus has been implicated in the pathogenesis of several diseases. These include multiple myeloma (MM), Waldenstom's macroglobulinemia (WM), multicentric Castleman's disease (MCD), body cavity-based lymphoma (BCBL), and various other conditions such as sarcoidosis and pemphigus. While the causative role of the viral infection is fairly certain in the development of BCBL and multicentric Castleman's disease, HHV-8 may act through a different mechanism to induce plasma cell malignancies. It has been suggested though the finding is still controversial - that infection of bone marrow stromal dendritic cells by HHV-8 might be a key factor in the etiology and pathogenesis of monoclonal gammopathies. The aim of this review is to provide a short introduction into the tumorigenic potential of HHV-8 as well as to detail the available data and possible mechanisms on the involvement of this virus in different hematologic diseases.  (+info)

Ultrasound B-mode changes in the uterus and ovaries and Doppler changes in the uterus after total body irradiation and allogeneic bone marrow transplantation in childhood. (8/1889)

Internal genitalia and uterine blood flow were assessed by ultrasound in 12 females 4.0-10.9 years after total body irradiation and allogeneic bone marrow transplantation for childhood leukaemia or lymphoma. Median age of the participants was 12.7 years (range 6.1-17.6) at bone marrow transplantation and 21.5 years (11.6-25.6) at the follow-up study. At follow-up all had entered puberty and 11/12 females had experienced the menarche. Eight females received sex steroid replacement therapy, three had spontaneous pubertal development and one woman experienced symptoms of estrogen deficiency. Median uterine and ovarian volumes were significantly reduced to -2.6 standard deviation scores (SDS) (-6.3 to -0.6), P = 0.002, and -2.6 SDS (-4.8 to -0.5), P = 0.002, respectively, compared with normal controls. Follicles were only detectable in two individuals. Uterine blood flow was impaired, as a systolic blood flow could be measured in 6/9 individuals, and a diastolic blood flow in 1/9 females. Our results indicate that the prescribed dosage of hormone replacement therapy, which was sufficient to induce bleeding and suppress other stigmata of premature menopause, was inadequate to generate normal uterine growth. In order to achieve uterine growth higher doses of hormone replacement therapy may be required. Our results confirm pelvic ultrasound as a reliable tool for investigation of internal female genitalia; however, in an infertility setting further tests are indicated.  (+info)

Hematologic neoplasms, also known as hematological malignancies, are a group of diseases characterized by the uncontrolled growth and accumulation of abnormal blood cells or bone marrow cells. These disorders can originate from the myeloid or lymphoid cell lines, which give rise to various types of blood cells, including red blood cells, white blood cells, and platelets.

Hematologic neoplasms can be broadly classified into three categories:

1. Leukemias: These are cancers that primarily affect the bone marrow and blood-forming tissues. They result in an overproduction of abnormal white blood cells, which interfere with the normal functioning of the blood and immune system. There are several types of leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML).
2. Lymphomas: These are cancers that develop from the lymphatic system, which is a part of the immune system responsible for fighting infections. Lymphomas can affect lymph nodes, spleen, bone marrow, and other organs. The two main types of lymphoma are Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).
3. Myelomas: These are cancers that arise from the plasma cells, a type of white blood cell responsible for producing antibodies. Multiple myeloma is the most common type of myeloma, characterized by an excessive proliferation of malignant plasma cells in the bone marrow, leading to the production of abnormal amounts of monoclonal immunoglobulins (M proteins) and bone destruction.

Hematologic neoplasms can have various symptoms, such as fatigue, weakness, frequent infections, easy bruising or bleeding, weight loss, swollen lymph nodes, and bone pain. The diagnosis typically involves a combination of medical history, physical examination, laboratory tests, imaging studies, and sometimes bone marrow biopsy. Treatment options depend on the type and stage of the disease and may include chemotherapy, radiation therapy, targeted therapy, immunotherapy, stem cell transplantation, or a combination of these approaches.

Leukemia is a type of cancer that originates from the bone marrow - the soft, inner part of certain bones where new blood cells are made. It is characterized by an abnormal production of white blood cells, known as leukocytes or blasts. These abnormal cells accumulate in the bone marrow and interfere with the production of normal blood cells, leading to a decrease in red blood cells (anemia), platelets (thrombocytopenia), and healthy white blood cells (leukopenia).

There are several types of leukemia, classified based on the specific type of white blood cell affected and the speed at which the disease progresses:

1. Acute Leukemias - These types of leukemia progress rapidly, with symptoms developing over a few weeks or months. They involve the rapid growth and accumulation of immature, nonfunctional white blood cells (blasts) in the bone marrow and peripheral blood. The two main categories are:
- Acute Lymphoblastic Leukemia (ALL) - Originates from lymphoid progenitor cells, primarily affecting children but can also occur in adults.
- Acute Myeloid Leukemia (AML) - Develops from myeloid progenitor cells and is more common in older adults.

2. Chronic Leukemias - These types of leukemia progress slowly, with symptoms developing over a period of months to years. They involve the production of relatively mature, but still abnormal, white blood cells that can accumulate in large numbers in the bone marrow and peripheral blood. The two main categories are:
- Chronic Lymphocytic Leukemia (CLL) - Affects B-lymphocytes and is more common in older adults.
- Chronic Myeloid Leukemia (CML) - Originates from myeloid progenitor cells, characterized by the presence of a specific genetic abnormality called the Philadelphia chromosome. It can occur at any age but is more common in middle-aged and older adults.

Treatment options for leukemia depend on the type, stage, and individual patient factors. Treatments may include chemotherapy, targeted therapy, immunotherapy, stem cell transplantation, or a combination of these approaches.

Pancreatic neoplasms refer to abnormal growths in the pancreas that can be benign or malignant. The pancreas is a gland located behind the stomach that produces hormones and digestive enzymes. Pancreatic neoplasms can interfere with the normal functioning of the pancreas, leading to various health complications.

Benign pancreatic neoplasms are non-cancerous growths that do not spread to other parts of the body. They are usually removed through surgery to prevent any potential complications, such as blocking the bile duct or causing pain.

Malignant pancreatic neoplasms, also known as pancreatic cancer, are cancerous growths that can invade and destroy surrounding tissues and organs. They can also spread (metastasize) to other parts of the body, such as the liver, lungs, or bones. Pancreatic cancer is often aggressive and difficult to treat, with a poor prognosis.

There are several types of pancreatic neoplasms, including adenocarcinomas, neuroendocrine tumors, solid pseudopapillary neoplasms, and cystic neoplasms. The specific type of neoplasm is determined through various diagnostic tests, such as imaging studies, biopsies, and blood tests. Treatment options depend on the type, stage, and location of the neoplasm, as well as the patient's overall health and preferences.

Neoplasms are abnormal growths of cells or tissues in the body that serve no physiological function. They can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow growing and do not spread to other parts of the body, while malignant neoplasms are aggressive, invasive, and can metastasize to distant sites.

Neoplasms occur when there is a dysregulation in the normal process of cell division and differentiation, leading to uncontrolled growth and accumulation of cells. This can result from genetic mutations or other factors such as viral infections, environmental exposures, or hormonal imbalances.

Neoplasms can develop in any organ or tissue of the body and can cause various symptoms depending on their size, location, and type. Treatment options for neoplasms include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, among others.

An encyclopedia is a comprehensive reference work containing articles on various topics, usually arranged in alphabetical order. In the context of medicine, a medical encyclopedia is a collection of articles that provide information about a wide range of medical topics, including diseases and conditions, treatments, tests, procedures, and anatomy and physiology. Medical encyclopedias may be published in print or electronic formats and are often used as a starting point for researching medical topics. They can provide reliable and accurate information on medical subjects, making them useful resources for healthcare professionals, students, and patients alike. Some well-known examples of medical encyclopedias include the Merck Manual and the Stedman's Medical Dictionary.

Acute myeloid leukemia (AML) is a type of cancer that originates in the bone marrow, the soft inner part of certain bones where new blood cells are made. In AML, the immature cells, called blasts, in the bone marrow fail to mature into normal blood cells. Instead, these blasts accumulate and interfere with the production of normal blood cells, leading to a shortage of red blood cells (anemia), platelets (thrombocytopenia), and normal white blood cells (leukopenia).

AML is called "acute" because it can progress quickly and become severe within days or weeks without treatment. It is a type of myeloid leukemia, which means that it affects the myeloid cells in the bone marrow. Myeloid cells are a type of white blood cell that includes monocytes and granulocytes, which help fight infection and defend the body against foreign invaders.

In AML, the blasts can build up in the bone marrow and spread to other parts of the body, including the blood, lymph nodes, liver, spleen, and brain. This can cause a variety of symptoms, such as fatigue, fever, frequent infections, easy bruising or bleeding, and weight loss.

AML is typically treated with a combination of chemotherapy, radiation therapy, and/or stem cell transplantation. The specific treatment plan will depend on several factors, including the patient's age, overall health, and the type and stage of the leukemia.

Bone marrow is the spongy tissue found inside certain bones in the body, such as the hips, thighs, and vertebrae. It is responsible for producing blood-forming cells, including red blood cells, white blood cells, and platelets. There are two types of bone marrow: red marrow, which is involved in blood cell production, and yellow marrow, which contains fatty tissue.

Red bone marrow contains hematopoietic stem cells, which can differentiate into various types of blood cells. These stem cells continuously divide and mature to produce new blood cells that are released into the circulation. Red blood cells carry oxygen throughout the body, white blood cells help fight infections, and platelets play a crucial role in blood clotting.

Bone marrow also serves as a site for immune cell development and maturation. It contains various types of immune cells, such as lymphocytes, macrophages, and dendritic cells, which help protect the body against infections and diseases.

Abnormalities in bone marrow function can lead to several medical conditions, including anemia, leukopenia, thrombocytopenia, and various types of cancer, such as leukemia and multiple myeloma. Bone marrow aspiration and biopsy are common diagnostic procedures used to evaluate bone marrow health and function.

Myelodysplastic syndromes (MDS) are a group of diverse bone marrow disorders characterized by dysplasia (abnormal development or maturation) of one or more types of blood cells or by ineffective hematopoiesis, resulting in cytopenias (lower than normal levels of one or more types of blood cells). MDS can be classified into various subtypes based on the number and type of cytopenias, the degree of dysplasia, the presence of ring sideroblasts, and cytogenetic abnormalities.

The condition primarily affects older adults, with a median age at diagnosis of around 70 years. MDS can evolve into acute myeloid leukemia (AML) in approximately 30-40% of cases. The pathophysiology of MDS involves genetic mutations and chromosomal abnormalities that lead to impaired differentiation and increased apoptosis of hematopoietic stem and progenitor cells, ultimately resulting in cytopenias and an increased risk of developing AML.

The diagnosis of MDS typically requires a bone marrow aspiration and biopsy, along with cytogenetic and molecular analyses to identify specific genetic mutations and chromosomal abnormalities. Treatment options for MDS depend on the subtype, severity of cytopenias, and individual patient factors. These may include supportive care measures, such as transfusions and growth factor therapy, or more aggressive treatments, such as chemotherapy and stem cell transplantation.

Leukemia, myeloid is a type of cancer that originates in the bone marrow, where blood cells are produced. Myeloid leukemia affects the myeloid cells, which include red blood cells, platelets, and most types of white blood cells. In this condition, the bone marrow produces abnormal myeloid cells that do not mature properly and accumulate in the bone marrow and blood. These abnormal cells hinder the production of normal blood cells, leading to various symptoms such as anemia, fatigue, increased risk of infections, and easy bruising or bleeding.

There are several types of myeloid leukemias, including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). AML progresses rapidly and requires immediate treatment, while CML tends to progress more slowly. The exact causes of myeloid leukemia are not fully understood, but risk factors include exposure to radiation or certain chemicals, smoking, genetic disorders, and a history of chemotherapy or other cancer treatments.

A bone marrow examination is a medical procedure in which a sample of bone marrow, the spongy tissue inside bones where blood cells are produced, is removed and examined. This test is used to diagnose or monitor various conditions affecting blood cell production, such as infections, leukemia, anemia, and other disorders of the bone marrow.

The sample is typically taken from the hipbone (iliac crest) or breastbone (sternum) using a special needle. The procedure may be done under local anesthesia or with sedation to minimize discomfort. Once the sample is obtained, it is examined under a microscope for the presence of abnormal cells, changes in cell size and shape, and other characteristics that can help diagnose specific conditions. Various stains, cultures, and other tests may also be performed on the sample to provide additional information.

Bone marrow examination is an important diagnostic tool in hematology and oncology, as it allows for a detailed assessment of blood cell production and can help guide treatment decisions for patients with various blood disorders.

Page 99 in: Sun T (2009). Atlas of hematologic neoplasms. Dordrecht New York: Springer. ISBN 978-0-387-89848-3. OCLC 432709321 ... Flow cytometry and immunohistochemistry for hematologic neoplasms. Philadelphia: Lippincott Williams & Wilkins. ISBN 978-0-7817 ... Where a defined exposure to past chemotherapy, radiotherapy, toxin or hematologic malignancy is known, this is termed secondary ... May 2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. ...
Acute leukemia, Hematologic malignant neoplasms). ...
Bernatsky S, Clarke AE, Suissa S (February 2008). "Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis ... Myeloproliferative neoplasms, including acute leukemia, non-Hodgkin lymphoma and multiple myeloma, occurred in 5 of 119 ...
... (BPDCN) is a rare hematologic malignancy. It was initially regarded as a form of ... The neoplasm occurs in individuals of all ages but predominates in the elderly; in children, it afflicts males and females ... Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy with features of cutaneous lymphoma (e.g. malignant ... Blastic plasmacytoid dendritic cell neoplasm occurs in children, including neonates, but is more common in adults, particularly ...
TLS is most common during cytotoxic treatment of hematologic neoplasms. Risk factors for tumor lysis syndrome depend on several ...
Articles with short description, Short description is different from Wikidata, Hematologic malignant neoplasms). ...
It is usually due to an underlying immunoproliferative disorder or hematologic neoplasms, especially multiple myeloma. It is ...
Like the latter neoplasm, hematologic neoplasms cause by ETV6-JAK2 and BCR-JAK2 are aggressive and progress rapidly. Too few ... lymphoid neoplasms, or features of both types of neoplasms. Most commonly, the present with features of myeloid neoplasms with ... A classic example of such a disease is chronic myelogenous leukemia, a neoplasm commonly caused by a mutation that creates the ... Further studies may allow these mutation-related diseases to be considered for inclusion in the myeloid and lymphoid neoplasms ...
pDCs that undergo malignant transformation cause a rare hematologic disorder, blastic plasmacytoid dendritic cell neoplasm. In ... Wang S, Wang X, Liu M, Bai O (April 2018). "Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel ... Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare type of myeloid cancer in which malignant pDCs infiltrate the ... Blastic plasmacytoid dendritic cell neoplasm has a high rate of recurrence following initial treatments with various ...
Blastic plasmacytoid dendritic cell neoplasm: A rare hematologic malignancy which is a malignancy of plasmacytoid dendritic ...
The protein was identified during investigations on the origin of multiple myeloma, a B-cell hematologic neoplasm. To ...
v t e (Articles with short description, Short description is different from Wikidata, Hematologic neoplasms, All stub articles ... The French-American-British (FAB) classification systems refers to a series of classifications of hematologic diseases. It is ...
Valent investigates the phenotype of these cells in various hematologic neoplasms and develops concepts predicting the step- ...
Hematologic malignant neoplasms). ... or other B cell-associated neoplasm, that has developed, often ... μ Heavy chain disease presents with a picture of a lymphoid neoplasm resembling either chronic lymphocytic leukemia or small ... "UpToDate". Warsame R, Yanamandra U, Kapoor P (2017). "POEMS Syndrome: an Enigma". Current Hematologic Malignancy Reports. 12 (2 ... of patients lack any evidence of a lymphoplasmacytic neoplasm. A majority of the latter patients have an autoimmune disease or ...
Hematologic malignant neoplasms, Lymphoma, Rare cancers, Vascular-related cutaneous conditions). ... ISBN 978-0-7817-5007-3. Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and ... List of hematologic conditions Waldenström hyperglobulinemic purpura "Waldenström macroglobulinemia". Cambridge Dictionary. ...
Hematologic malignant neoplasms). ... neoplasms with germline DDX41 mutation Myeloid neoplasms with ... RUNX1 mutation Myeloid neoplasms with germline ANKRD26 mutation Myeloid neoplasms with germline ETV6 mutation Myeloid neoplasms ... neoplasms with PDGFRA rearrangement Myeloid/lymphoid neoplasms with PDGFRB rearrangement Myeloid/lymphoid neoplasms with FGFR1 ... NOS Lymphoid neoplasms Precursor lymphoid neoplasms B-lymphoblastic leukaemia/lymphoma, NOS B-lymphoblastic leukaemia/lymphoma ...
Hematologic malignant neoplasms). ...
... myeloma Non hematologic neoplasms Causes of polyclonal secondary cold agglutinin disease include the following: Mycoplasma ... Causes of the monoclonal secondary disease include the following: B-cell neoplasms - Waldenström macroglobulinemia, lymphoma, ... This may suggest a close association between systemic rheumatic disease and autoimmune hematologic abnormalities. Hyperreactive ...
Hematologic malignant neoplasms, Lymphoid-related cutaneous conditions, Epstein-Barr virus-associated diseases). ...
Matutes E (May 2018). "The 2017 WHO update on mature T- and natural killer (NK) cell neoplasms". International Journal of ... Taylor J, Xiao W, Abdel-Wahab O (July 2017). "Diagnosis and classification of hematologic malignancies on the basis of genetics ... Ondrejka S, Jagadeesh D (December 2016). "Enteropathy-Associated T-Cell Lymphoma". Current Hematologic Malignancy Reports. 11 ( ... Cahu X, Constantinescu SN (December 2015). "Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin ...
List of hematologic conditions Chen BJ, Chuang SS (March 2020). "Lymphoid Neoplasms With Plasmablastic Differentiation: A ... This lymphoma also belongs to a group of lymphoid neoplasms with plasmablastic differentiation that involve malignant ... "Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the ...
... have been shown to be central to myeloproliferative neoplasms and JAK kinases play a central role in driving hematologic ... "Myeloproliferative Neoplasms" (PDF). NCCN Clinical Practice Guidelines. National Cancer Comprehensive Network. 15 November 2021 ... Other similar but truly Ph-negative conditions are considered CML-like myeloproliferative neoplasms.) However, the presence of ...
... neoplasm, most commonly cervical cancer, and hematologic disorders. Molar pregnancy (also called hydatiform mole) is a type of ...
... of all germ cell neoplasms. Syndromes associated with mediastinal germ cell tumors include Hematologic Neoplasia and ... C R Nichols; N A Heerema; C Palmer (1987). "Klinefelter's syndrome associated with mediastinal germ cell neoplasms". Journal of ...
Thus, these pharmacologic inhibitors have their greatest clinical utility in the treatment of hematologic diseases in which ... the myeloproliferative neoplasms. Given LSD1 is critical for the maturation of megakaryocytes, the bone marrow cells that ... and tranylcypromine are in clinical development for the treatment of hematologic malignancies including acute meyloid leukemeia ...
... hematologic disorders; organ transplant; recent gastrointestinal, obstetric, or gynecologic surgery; malignant neoplasms ...
As of April 2023, six CAR-T cell therapies are clinically approved by the FDA, all of which target hematologic (blood-based) ... Solid tumors, which typically take the form of neoplasms in epithelial cells or in bones, tissue, or adipose (fat), are ... These "scaffold factories" have shown to function in targeting hematologic cancers and show promise in future research to ... While this delivery method is reliable for hematologic cancers, as demonstrated by successful clinical trials and FDA ...
EMH in the lymph nodes is usually associated with underlying hematopoietic neoplasms. Myeloproliferative neoplasms (MPNs) tend ... If EMH is identified in the lymph nodes of an adult or infant, a hematologic evaluation, including blood cell counts, ... Hematologic Pathology. 1 (1): 77-80. PMID 3332874. MacSween RM, Burt AD, Portmann BC, Ishak KG, Scheurer PJ, Anthony PP, ... para-nasal sinuses and numerous types of benign/malignant neoplasms. The most common sites of EMH associated with neoplastic ...
Mutations in PDGFRA, are associated with an array of clinically significant neoplasms, notably ones of the clonal ... particularly hematologic tissues, throughout life. ... which is the most common mesenchymal neoplasm of the ... myeloproliferative neoplasm/myeloblastic leukemia; a T-lymphoblastic leukemia/lymphoma; or myeloid sarcoma; b) are diagnosed ... a form of myeloproliferative neoplasm/myeloblastic leukemia associated with little or no eosinophilia; c) T-lymphoblastic ...
Candidatus Neoehrlichia mikurensis Infection in Patient with Antecedent Hematologic Neoplasm, Spain1 On This Page ... Candidatus Neoehrlichia mikurensis Infection in Patient with Antecedent Hematologic Neoplasm, Spain. Emerging Infectious ... Candidatus Neoehrlichia mikurensis Infection in Patient with Antecedent Hematologic Neoplasm, Spain. Volume 29, Number 8-August ... Candidatus Neoehrlichia mikurensis Infection in Patient with Antecedent Hematologic Neoplasm, Spain. Emerg Infect Dis. 2023;29( ...
Allogeneic Transplantation for Hematologic Neoplasms in Adults. By Syed Ali Abutalib, MD, and Stephen J. Forman, MD. March 25, ... 8. Baliakas P, Tesi B, Wartiovaara-Kautto U, et al: Nordic guidelines for germline predisposition to myeloid neoplasms in ... are several abstracts selected from the meeting proceedings focusing on allogeneic transplantation for hematologic neoplasms in ... Background: Setting the diagnosis of myeloid neoplasms with germline predisposition is becoming increasingly recognized as ...
A download flow cytometry immunohistochemistry and molecular genetics for hematologic neoplasms relevant to those been in these ... Download Flow Cytometry Immunohistochemistry And Molecular Genetics For Hematologic Neoplasms. Cham: Springer International ... maybe since the download flow cytometry immunohistochemistry and molecular genetics for hematologic neoplasms of this basic ... download flow cytometry immunohistochemistry and molecular genetics for hematologic neoplasms: Springer, 2017. Madrid: ...
Hematologic Neoplasms online from Zookal AU and start savings. Get 10% off Textbooks + Free Shipping Now when you sign up with ... Flow Cytometry, Immunochemistry and Molecular Genetics for Hematologic Neoplasms. Sun · ISBN 9781608316168 ... Immunophenotyping is the most powerful tool in the routine diagnosis of hematologic neoplasms. Immunohistochemical technique is ...
Page 99 in: Sun T (2009). Atlas of hematologic neoplasms. Dordrecht New York: Springer. ISBN 978-0-387-89848-3. OCLC 432709321 ... Flow cytometry and immunohistochemistry for hematologic neoplasms. Philadelphia: Lippincott Williams & Wilkins. ISBN 978-0-7817 ... Where a defined exposure to past chemotherapy, radiotherapy, toxin or hematologic malignancy is known, this is termed secondary ... May 2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. ...
Colorectal Neoplasms / prevention & control * Female * Hematologic Neoplasms / etiology * Humans * Lung Neoplasms / prevention ...
Centre of Expertise for hematologic neoplasms. Azienda Ospedaliero Universitaria Senese - Policlinico Santa Maria alle Scotte. ... Regional Centre of Expertise for rare hematologic diseases. Azienda Ospedaliera Ospedali Riuniti "Villa Sofia-Cervello" - ... Centre of Expertise for pediatric hematologic and oncohematologic diseases. IRCCS Azienda Ospedaliero Universitaria di Bologna ...
Hematologic Neoplasms / complications * Hematologic Neoplasms / mortality * Hematologic Neoplasms / therapy * Hematopoietic ...
The NHLs constitute a heterogeneous group of lymphoid system neoplasms with varying presentations, natural histories, and ... Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 2008 Apr 15. 111(8):3941-67. [QxMD MEDLINE Link]. ... 24] A number of cytogenetic abnormalities have been reported in these neoplasms, including t(14;18), t(8;14), trisomy 12, and ... The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May 19. 127 (20):2375-90. ...
... with an associated hematologic neoplasm (SM-AHN) comprises 5% to 40% of cases of SM. All types of hematologic neoplasms have ... There was evident dysgranulopoiesis that raised a provisional diagnosis of myelodysplastic/myeloproliferative neoplasm. Bone ... with an associated hematologic neoplasm (SM-AHN) comprises 5% to 40% of cases of SM. All types of hematologic neoplasms have ... A Rare Case of Systemic Mastocytosis with Associated Hematologic Neoplasm (SM-AHN) Involving Chronic Myeloid Leukemia: A Case ...
... hematologic malignant neoplasm of childhood, with a higher incidence of two and five years old, and it is 25% of all cancers in ... "hematologic neoplasms" and 4# "prognosis". The crosses were performed using the Boolean AND operator: 1# AND 2#, 1# AND 2# AND ... Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. Eur J Cancer. ... The hairy cell leukemia (HCL) is also an unusual and barely frequent hematologic tumor subtype. In Mexico, the disease is about ...
Hematologic Neoplasms. 1030. hematologic cancer. 1030. leukemia. 612. myeloid leukemia. 409. acute myeloid leukemia. 337. ... Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic ...
Hematologic & oncologic: Malignant neoplasm of breast. Hypersensitivity: Angioedema, hypersensitivity reaction. Infection: ...
Impact of bone marrow fibrosis on the prognosis of myeloproliferative neoplasms and other hematologic malignancies. ... BMF is seen in many hematologic and non-hematologic conditions and is a prominent pathologic feature of MF. The extent to which ... 21 There are a number of hematologic and non-hematologic disorders that are associated with increased BMF (Table 2).3 ... Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369(25):2391-2405. PubMedhttps ...
Paraneoplastic syndromes are rare disorders that are triggered by an altered immune system response to a neoplasm. They are ... Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal ... Wang A, Zeidan A, Brunet C. Rheumatologic manifestations of hematologic neoplasms. Curr Rheumatol Rev. 2016 Aug 15. 31(9):1854- ... Other hematologic syndromes are as follows:. * Marantic endocarditis is typical of mucous adenocarcinomas of lung, stomach, and ...
Hematologic neoplasm 1 0.2 1 0.2 1. •There were no toxic deaths ... Abnormal renal, liver, or hematologic function. • Other serious ...
Hematologic Neoplasms (Hematological Malignancy) 10/01/2011 - "Allogeneic hematopoietic cell transplantation (HCT) is a ... 08/01/2011 - "Haploidentical hematopoietic cell transplantation (HCT) has been used to treat hematologic malignancies, but it ... is the transplantation of stem cells from a donor and an effective treatment for many hematologic malignancies. ". 01/01/2006 ... after myeloablative conditioning regimens has been an effective treatment for many patients with hematologic malignancies or ...
Flow Cytometry and Immunohistochemistry for Hematologic Neoplasms (Sun). 209.00. Gastrointestinal Pathology: An Atlas and Text ...
Hematologic neoplasms such as acute myelogenous leukemia have been documented to occur with chronic exposures as low as 10 ppm ... Other neoplasms have been documented in animal models. Reproductive and Developmental Effects. Benzene is not included in ... Chronic benzene exposure in the workplace has been associated with hematologic disorders (i.e., thrombocytopenia, aplastic ...
However, none of these is an established risk factor for hematologic neoplasms. Smoking, a well-established risk factor for ... Moreover, our study indicated that persistent use of statins is associated with reduced risk of hematopoietic neoplasms, for ... Statin use and risk of lymphoid neoplasms: results from the European Case-Control Study EPILYMPH. Cancer Epidemiol Biomarkers ... published between 1996 and 2006 indicated an insignificant inverse association between statin use and the risk of hematologic ...
Hematology, Hemotherapy Service, Bone Marrow Transplantation, Cell- and Tissue-Based Therapy, Hematologic Diseases, Neoplasms ... Medical Oncology, Radiotherapy, Hematology, Genital Neoplasms, Female, Breast, Prostate Board Review: XVI Curso de Revisão em ...
Test ID: P53CA: Hematologic Neoplasms, TP53 Somatic Mutation, DNA Sequencing Exons 4-9: Clinical and Interpretive; [cited 2022 ...
Bone Marrow and Lymphatic Tissue Cancer (Hematologic Neoplasm). *Chronic B-Cell Lymphocytic Leukemia ...
Hematologic neoplasm of uncertain behavior 109958007. Lymphoproliferative disorder following lung transplant 122501000119101. ... Neoplasm and/or hamartoma 399981008. Neoplastic disease 55342001. Neoplastic disease of uncertain behavior 118616009. ... Neoplasm and/or hamartoma 399981008. Neoplastic disease 55342001. Neoplastic disease of uncertain behavior 118616009. ...
Revision of Laboratory Testing Guidelines for Initial Diagnosis of Hematologic Neoplasms Kim IS, Lee JY, Kong SY, Lee ST, Huh J ... Diagnostic Approach for Acute Myeloid Leukemia Based on the World Health Organization Classification of Hematologic Neoplasms ... Acute myeloid leukemias (AMLs) are heterogeneous hematologic neoplasms characterized by myeloblast or promyelocyte ... Status of Next-Generation Sequencing-Based Genetic Diagnosis in Hematologic Malignancies in Korea (2017-2018) Kim J, Lee JY, ...
Figure 7 presents the results of the meta-analysis of eight studies on mortality in patients with hematologic neoplasms. The ... Among the 35 studies, 30 reported results for all cancers combined, and 8 for hematologic neoplasms (3 of these reported both ... Results for patients with hematologic and solid neoplasms were compared in some individual studies. In particular, Desai et al ... As mentioned above, we were not able to analyze specific cancers other than hematologic neoplasms, because results were too ...
Researchers with interest in hematologic malignancies and myeloproliferative neoplasms in general,. and CML in particular ...
PD-L1 is expressed in a variety of cell types and tissues such as solid or hematologic neoplasms; when PD-L1 is expressed in ... which has led to the use of immunotherapy for other neoplasms, including BC (100). Similarly, the Immunoscore, which was first ... and their possible involvement in the development of neoplasms (96-98). The number of publications on cancer and immune ... although low grade triple-negative neoplasms have been reported (12). Several studies have shown lower 5-year survival rates in ...
All hematologic neoplasms developed in the 287 patients with mediastinal nonseminomatous germ cell tumors, for a 2% incidence ... Hematologic neoplasms have included acute myeloid leukemia, acute nonlymphocytic leukemia, acute lymphocytic leukemia, ... Recent evidence indicates that the hematologic neoplasms in this setting are not treatment related, but rather arise from ... However, the specific association of leukemias and other hematologic neoplasms with mediastinal nonseminomatous germ cell ...
  • In a series of 635 patients with extragonadal germ cell tumors, 17 patients developed hematologic malignancies at a median of 6 months after the extragonadal germ cell tumor was diagnosed. (health.am)
  • Ataxia telangiectasia (AT) is a rare autosomal recessive disease, characterised by cerebella ataxia, immunodeficiency, increased sensitivity to ionising radiation, and a predisposition to malignancies, especially lymphoid neoplasms. (bmj.com)
  • Would you Consider to carry PSYCHOLOGICAL download flow cytometry immunohistochemistry and molecular genetics for hematologic neoplasms or handling in this subject? (binaryinfo.com)
  • We report a confirmed case of Candidatus Neoehrlichia mikurensis infection in a woman in Spain who had a previous hematologic malignancy. (cdc.gov)
  • Where a defined exposure to past chemotherapy, radiotherapy, toxin or hematologic malignancy is known, this is termed secondary AML. (wikipedia.org)
  • Scholars@Duke publication: How Caregivers Cope and Adapt When a Family Member Is Diagnosed With a Hematologic Malignancy: Informing Supportive Care Needs. (duke.edu)
  • Informal family caregivers (FCs) of adults with various diseases including hematologic malignancy (HM) experience low quality of life and psychological well-being. (duke.edu)
  • In our practice, hematologic neoplasms are mainly lymphoproliferative syndromes and the most common varieties are non-Burkitt non Hodgkin lymphoma, high grade lymphomas, chronic lymphocytic lymphoma and multiple myeloma. (bvsalud.org)
  • Acute myeloid leukemias (AMLs) are heterogeneous hematologic neoplasms characterized by myeloblast or promyelocyte proliferation without normal differentiation. (koreamed.org)
  • In the recent fifth edition of the World Health Organization classification, similar to the recent update to the International Consensus Classification, the category was renamed to "myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions" and both classifications added novel subtypes with new JAK2 rearrangements (e.g. (nature.com)
  • 3 Myelofibrosis (MF) refers to the Philadelphia chromosome ( BCR-ABL1 )-negative myeloproliferative neoplasm (MPN) originating at the level of the multipotent hematopoietic stem cell. (haematologica.org)
  • The pooled mortality OR for hematologic neoplasms was 2.14 (95% CI 1.87-2.44, I 2 20.8%, 8 studies). (elifesciences.org)
  • Immunophenotyping is the most powerful tool in the routine diagnosis of hematologic neoplasms. (jekkle.com.au)
  • There was evident dysgranulopoiesis that raised a provisional diagnosis of myelodysplastic/myeloproliferative neoplasm. (amjcaserep.com)
  • Percutaneous ethanol injection (PEI) for liver neoplasms when criteria above are not met. (aetna.com)
  • Hematologic Neoplasia A unique association between mediastinal nonseminomatous germ cell tumors and a variety of hematologic neoplasms is now well described. (health.am)
  • All hematologic neoplasms developed in the 287 patients with mediastinal nonseminomatous germ cell tumors, for a 2% incidence in this group. (health.am)
  • Recent evidence indicates that the hematologic neoplasms in this setting are not treatment related, but rather arise from clones of malignant lymphoblasts or myeloblasts contained within the mediastinal germ cell tumor. (health.am)
  • More importantly, several patients have had an identical chromosomal abnormality (an isochromosome of the short arm of chromosome 12) in the neoplastic cells from the mediastinal germ cell tumor and the hematologic neoplasm, providing strong evidence for a common origin. (health.am)
  • However, the specific association of leukemias and other hematologic neoplasms with mediastinal nonseminomatous germ cell tumors, rather than with all germ cell tumors, remains unexplained. (health.am)
  • In addition to hematologic neoplasia, several cases of idiopathic thrombocytopenia in association with mediastinal nonseminomatous germ cell tumors have been reported. (health.am)
  • This download flow cytometry immunohistochemistry and molecular genetics for hematologic is summarised arrived as cause of BMC Health Services Research world 11 today 2, 2011: biomedical concern: illuminating the Seaweed premise into series rebirth hospital and contracting. (binaryinfo.com)
  • Amazon Giveaway is you to deliver many rivers in download flow cytometry immunohistochemistry and molecular genetics for hematologic to send attempt, load your Philosophy, and add ergodic issues and cookies. (binaryinfo.com)
  • As download flow cytometry immunohistochemistry and molecular genetics for hematologic of the perspective, India's recipe wrote that a ergodic departure of the stakeholder warned from due concepts. (binaryinfo.com)
  • To complement The ASCO Post 's continued comprehensive coverage of the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on allogeneic transplantation for hematologic neoplasms in adults. (ascopost.com)
  • Patients with hematologic myeloproliferative neoplasms (MPNs)-a group of rare blood diseases that include myelofibrosis, essential thrombocythemia (ET), and polycythemia vera (PV)-should take a more active role in their treatment plan, according to experts in oncology pharmacy who participated in a Pharmacy Times clinical forum at ASCO 2023 in Chicago, Illinois. (pharmacytimes.com)
  • Mutations on epigenetic regulator genes are common in clonal hematopoiesis and may be a risk factor for HEMATOLOGIC NEOPLASMS and other cardiovascular diseases. (bvsalud.org)
  • Modulation and response of the immune system are of interest in cancer treatment due to the success of immunotherapy in the treatment of various neoplasms. (spandidos-publications.com)
  • A number of studies indicate that bone marrow fibrosis is an adverse prognostic variable in myeloproliferative neoplasms. (haematologica.org)
  • 16 had aggressive systemic mastocytosis, 57 had systemic mastocytosis with an associated hematologic neoplasm, and 16 had mast-cell leukemia. (uni-koeln.de)
  • Since then, several case series and individual cases of patients with Candidatus N. mikurensis infections have been described, mainly in persons who were immunosuppressed because of hematologic neoplasms, splenectomies, or immunosuppressive drug treatment ( 3 - 9 ). (cdc.gov)
  • Despite a slew of barriers with patient management, pharmacists have the training and resources to advocate for better patient care and help patients with hematologic myeloproliferative neoplasms advocate for themselves. (pharmacytimes.com)
  • Le protocole utilisé dans le traitement du myélome multiple a été le VMCD-REV à 76,92% avec pour réponse thérapeutique complète chez 6 patients, 3 réponses partielles et 4 en cours de traitement. (bvsalud.org)
  • This was a descriptive retrospective study lasting 2 years 3 months from January 1st, 2018 to March 31st, 2020 concerning 80 patients with hematologic neoplasms who were managed in the CNRAO. (bvsalud.org)
  • Systemic mastocytosis (SM) with an associated hematologic neoplasm (SM-AHN) comprises 5% to 40% of cases of SM. (amjcaserep.com)
  • BACKGROUND Advanced systemic mastocytosis comprises rare hematologic neoplasms that are associated with a poor prognosis and lack effective treatment options. (uni-koeln.de)
  • Hematologic neoplasms represented 2.2% of cancers (80/3650) at CNRAO, giving an annual incidence of 26.66 cases. (bvsalud.org)
  • Hematologic neoplasms are abnormal and anarchic proliferations of hematopoietic cells with a medullary or peripheral starting point. (bvsalud.org)
  • Il s'agissait d'une étude rétrospective descriptive d'une durée de 2 ans 3 mois allant du 1er janvier 2018 au 31 Mars 2020 portant sur 80 dossiers de malades porteurs d'hémopathies malignes et prise en charge dans le centre. (bvsalud.org)
  • Median survival was only 5 months after the hematologic disorder was diagnosed, and no patient survived for more than 2 years. (health.am)
  • This Clinical Policy Bulletin addresses treatment approaches for liver and other neoplasms. (aetna.com)
  • All types of hematologic neoplasms have been previously reported, although CML has been rarely encountered. (amjcaserep.com)
  • This study will evaluate the safety, tolerability, and efficacy of an engineered donor graft ('Orca-T', a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells) in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies. (researcherprofiles.org)
  • This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications. (researcherprofiles.org)
  • The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM). (researcherprofiles.org)
  • This study will compare the safety and efficacy between patients receiving an engineered donor graft ('Orca-T', a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells) or standard-of-care (SOC) control in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation (MA-alloHCT) for hematologic malignancies. (researcherprofiles.org)
  • t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm? (elsevierpure.com)
  • Of 17 patients with enough clinical information and pathological materials for review, 16 had a history of cytotoxic therapies for various malignancies including 12/15 patients who received topoisomerase II inhibitors, and 15 were classified as having therapy-related neoplasms. (elsevierpure.com)
  • Dive into the research topics of 't(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm? (elsevierpure.com)
  • 5. Clinical and biological activity of the interferons in hematologic malignancies. (nih.gov)
  • 9. Biotherapy with interferon in hematologic malignancies. (nih.gov)
  • 17. Interferon therapy of hematologic malignancies. (nih.gov)
  • In the past, partially HLA-mismatched related donor, or HLA-haploidentical, blood or marrow transplantation (haploBMT), for hematologic malignancies has been complicated by unacceptably high incidences of graft rejection or GvHD resulting from intense bi-directional alloreactivity. (johnshopkins.edu)
  • In the clinic, haploBMT with high-dose, post-transplantation cyclophosphamide is associated with acceptably low incidences of fatal graft rejection, GvHD and non-relapse mortality, and provides an acceptable treatment option for hematologic malignancies patients lacking suitably HLA-matched donors. (johnshopkins.edu)
  • Introduction: Epigenetic changes resulting from aberrant methylation patterns are a recurrent observation in hematologic malignancies. (wustl.edu)
  • This educational activity is based on case presentations and subsequent small group discussions of patients with hematologic malignancies that are being evaluated, treated and followed in the Department of Hematology and Oncology, and that have diagnostic or follow-up material evaluated in the Division of Hematopathology. (mcw.edu)
  • RESULTS: We analyzed 44 samples from 37 patients: 31 were solid organ transplant recipients, 4 had hematologic malignancies, 2 had autoimmune disorders. (umn.edu)
  • The recently developed International Consensus (IC) classification of hematologic neoplasms is primarily based on input from clinical advisory committees composed of pathologists, hematologists, oncologists, and genomic scientists. (nih.gov)
  • Fusion partners of KMT2A affect disease phenotype and influence the current World Health Organization classification of hematologic neoplasms. (elsevierpure.com)
  • Splenomegaly can occur with other hematologic disorders including leukemia and other myeloproliferative neoplasms, as well as nonmalignant causes (autoimmune or infection). (logicalimages.com)
  • 19. [Neutrophil function in hematologic disorders]. (nih.gov)
  • Our faculty and staff are experienced in the evaluation of common and uncommon hematologic neoplasms and related disorders. (upstate.edu)
  • The most comprehensive reference book on diagnosing cutaneous hematologic disorders available, Hematopathology of the Skin: Clinical and Pathological Approach, 2nd Edition, provides interdisciplinary guidance from more than 40 global experts in the fields of dermatopathology, dermatology, hematopathology, and hemato/oncology. (biggerbooks.com)
  • Grifols is extending its longtime expertise in Igs into disorders in which the immunodeficiency and low levels of Igs is a consequence of a disease (secondary immunodeficiency), such as some hematologic neoplasms like chronic lymphocytic leukemia (CLL). (grifols.com)
  • This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL). (researcherprofiles.org)
  • Hematologic neoplasms are a group of cancers that affect the blood, bone marrow, and lymphatic system. (centerwatch.com)
  • As the person who led the expert panel of pathologists and hematopathologists that wrote the evidence-based CAP Pathology and Laboratory Quality Center guideline on bone marrow synoptic reporting for hematologic neoplasms, Dr. Sever has come to understand the value of a synoptic format. (cap.org)
  • Unparalleled in scope, it is a well-written, easy-to-follow resource for clinicians who care for patients with cutaneous hematologic neoplasms. (biggerbooks.com)
  • Amongst them, pediatric cancers and rare hematologic neoplasms are often covered by dedicated educational events, while rare adult solid cancers are hardly grouped together and approached as a collective group of neoplasms. (eso.net)
  • Chromosome (G-banding) and fluorescence in situ hybridization (FISH) serve as the primary methodologies utilized for detecting genetic aberrations in hematologic neoplasms. (medscape.com)
  • Chromosomal microarray identified CNAs and CN-LOH of clinical significance, and could be performed on fresh or paraffin-embedded tissue and liquid neoplasms. (medscape.com)
  • The purpose of our review is to highlight a preselected group of hematologic neoplasms for which chromosomal microarray has the greatest clinical utility. (medscape.com)
  • The particular strengths are breast, GU and hematologic neoplasms, which relate well with research interests of the Keck School of Medicine faculty. (usc.edu)
  • 6. [Interferon therapy in hematologic neoplasms]. (nih.gov)
  • Here, we report 18 cases of hematologic neoplasms with t(11;16). (elsevierpure.com)
  • A case-based approach and review of the literature was performed to identify the advantages and disadvantages of utilizing chromosomal microarray for specific hematologic neoplasms. (medscape.com)